Description: This report has been written to provide a primer on the measurement known as R0 (pronounced “R-naught”), which is commonly used in epidemiology. The R0 metric has received extensive press coverage since the outbreak due to its importance in the measurement of the spread of COVID-19.

Description: This will be the most fun you'll ever have learning about applying health status based risk adjustment methodologies in the real world! Quantifying relative differences in the use of finite healthcare resources – due to differences in health status – isn't just fun, it's the very heart and soul of ASOP 45! Get ready for a rollercoaster of statistics, probability, and a few puns that might just make you laugh harder than a data outlier!

Description: Patients with chronic conditions such as musculoskeletal pain, diabetes, and hypertension impact 50% of the US healthcare population, consume more than 85% of healthcare costs, and often require a higher volume of care, expensive imaging, testing, and emergency procedures, and long-term high-cost drugs. Managing these conditions through innovative digital health interventions provides a significant opportunity for higher-touch and more-effective management that will result in lower costs.

Description: America’s healthcare results are lackluster and worsening despite enormous effort and investment over many decades. Spending, affordability, health, coverage, access, quality, and healthcare workforce results are suboptimal or poor. Too many are suffering, and the system is financially unsustainable. We need a new approach, a new way of thinking about healthcare financing and delivery.

Description: If you are a pricing actuary, you have probably been there. A new blockbuster drug has been introduced and the manufacturer is claiming that the value of the drug will offset the higher cost of the drug. But how do you know? In this session, presenters will discuss techniques for measuring the impact of a prescription drug on the total cost of care, including the benefits and limitations of each method.

Description: This presentation seeks to educate SOA attendees on how Medicare provides care for HIV-positive members. HIV is a disease that has occupied a prominent place in the public's view since its initial discovery. Initially a terminal condition for the afflicted population, advances in anti-retroviral pharmaceutical therapies transformed HIV into a chronic condition in the 1990s.

Description: This session, which borrows heavily from SOA studies, US government data, and Munich Re’s global health data, will explore the blending of Covid deaths into the new baseline mortality.

Description: Prescription drug affordability remains a critical concern for consumers, payers and policymakers alike. This paper discusses an alternative to policy solutions: reimagining commercial pharmacy financing using a value-based reimbursement model to increase transparency, encourage pharmaceutical competition, align stakeholder incentives and mitigate total cost of care (TCOC) increases.

Description: An in-depth analysis of the insurance landscape in China and seven key Asia Pacific Markets, focusing on the rapid development of critical illness products and the impact of technology on insurance purchasing behaviors.

Description: Underwriting smokers just got a lot more interesting. New research reveals that tobacco’s mortality is surprisingly durable and tenacious. Mortality is now shown to hover at 200% for years after a reported incidence of nicotine dependency, and smoking turns many common and manageable conditions into serious comorbidities with compounded mortality impact.